JPRN-jRCT2031220131招募中未知
Special drug use Surveillance for EFIENT Tablets- Patient with ischemic cerebrovascular disease with a high risk of ischemic stroke
Matsuoka Yomei0 个研究点目标入组 1,200 人开始时间: 2022年6月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who fulfilled the following criteria:
- •(1) Patients with ischemic cerebrovascular disease associated with large-artery atherosclerosis or small-vessel occlusion (restricted to cases with a high risk of ischemic stroke*1), who were administered EFIENT for the first time
- •*1: Patients with either hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease or a history of ischemic stroke before the last episode of attack
- •(2) Patients who started administration of EFIENT tablet during the contract period (contract period based on the contract with each medical site) and until 30/June/2023
- •(3) Patients from whom written informed consent was obtained
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Protocol Number; CLCZ696B1401Chronic Heart FailureJPRN-jRCT2031200432Sugimoto Toshiya660
招募中
Unknown
Post-marketing Surveillance Protocol Number;CLCZ696A1402HypertensionJPRN-jRCT2031230283Sugigmoto Toshiya1,000
未知
Unknown
iovel Combination Tablets special drug use surveillance Long-term use in patients with type 2 diabetes mellitusJPRN-jRCT1080222253TAKEDA PHARMACEUTICAL COMPANY LTD.3,000
招募中
不适用
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3
已完成
不适用
Special drug use results surveillance for the use of SIMPONI in ulcerative colitisulcerative colitisJPRN-UMIN000027542Janssen Pharmaceutical K.K.300